The process of obtaining blood biologics, including platelet-rich plasma (PRP) and platelet-rich fibrin (PRF), can be complicated and expensive and is influenced by many vendors and proprietary techniques. The indications for PRP/PRF use remain controversial, and complicated or expensive modes of generating this biologic may lead to many facial plastic surgeons to pass on the use of these potentially useful agents. The lack of standardization of PRP procurement also has led to difficulties in assessing clinical efficacy and comparing study protocols.